https://retacompare.com/news/glp-1-agonists-and-retatrutide-emerging-trends-in-obesity-treatment 2026-10-21T17:06:36.000Z RetatrutideCompare en 2026-10-21T17:06:36.000Z GLP-1 Agonists and Retatrutide: Emerging Trends in Obesity Treatment Market News, Retatrutide https://retacompare.com/news/incretin-drug-shows-potential-in-treating-sleep-apnea 2026-10-21T15:59:06.000Z RetatrutideCompare en 2026-10-21T15:59:06.000Z Incretin Drug Shows Potential in Treating Sleep Apnea Clinical Trials, Retatrutide https://retacompare.com/news/lab-tests-reveal-concerns-with-experimental-weight-loss-drug 2026-10-21T13:01:00.000Z RetatrutideCompare en 2026-10-21T13:01:00.000Z Lab Tests Reveal Concerns with Experimental Weight Loss Drug Weight Loss, Retatrutide https://retacompare.com/news/pennsylvania-medicaid-ends-coverage-for-obesity-medications 2026-10-21T12:49:00.000Z RetatrutideCompare en 2026-10-21T12:49:00.000Z Pennsylvania Medicaid Ends Coverage for Obesity Medications Market News, Retatrutide https://retacompare.com/news/gender-disparities-in-glp-1-usage-men-less-represented 2026-10-21T08:37:27.000Z RetatrutideCompare en 2026-10-21T08:37:27.000Z Gender Disparities in GLP-1 Usage: Men Less Represented Market News, Retatrutide https://retacompare.com/news/cosmetic-industry-adapts-to-changes-from-obesity-drug-use 2026-10-21T06:02:00.000Z RetatrutideCompare en 2026-10-21T06:02:00.000Z Cosmetic Industry Adapts to Changes from Obesity Drug Use Market News, Retatrutide https://retacompare.com/news/glp-1-drugs-and-cancer-risk-implications-for-retatrutide-safety 2026-10-21T04:11:28.000Z RetatrutideCompare en 2026-10-21T04:11:28.000Z GLP-1 Drugs and Cancer Risk: Implications for Retatrutide Safety Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-side-effects-discussed-on-reddit-amid-glp-1-research 2026-10-20T17:52:14.000Z RetatrutideCompare en 2026-10-20T17:52:14.000Z Retatrutide Side Effects Discussed on Reddit Amid GLP-1 Research Patient Experiences, Retatrutide https://retacompare.com/news/glp-1r-agonism-s-role-in-breast-cancer-a-potential-metabolic-oncogenic-link 2026-10-20T17:30:59.251Z RetatrutideCompare en 2026-10-20T17:30:59.251Z GLP-1R Agonism's Role in Breast Cancer: A Potential Metabolic-Oncogenic Link Clinical Trials, Retatrutide https://retacompare.com/news/factors-influencing-response-to-glp-1-agonists-in-obesity-treatment 2026-10-20T17:30:59.251Z RetatrutideCompare en 2026-10-20T17:30:59.251Z Factors Influencing Response to GLP-1 Agonists in Obesity Treatment Clinical Trials, Retatrutide https://retacompare.com/news/teen-discusses-daily-life-changes-from-glp-1-medication-use 2026-10-20T17:15:00.000Z RetatrutideCompare en 2026-10-20T17:15:00.000Z Teen Discusses Daily Life Changes from GLP-1 Medication Use Patient Experiences, Retatrutide https://retacompare.com/news/retatrutide-s-potential-to-overcome-glp-1-weight-loss-challenges 2026-10-20T14:03:06.000Z RetatrutideCompare en 2026-10-20T14:03:06.000Z Retatrutide's Potential to Overcome GLP-1 Weight-Loss Challenges Weight Loss, Retatrutide https://retacompare.com/news/novo-s-obesity-drug-achieves-25-weight-loss-in-women-in-late-stage-trial 2026-10-20T12:50:24.000Z RetatrutideCompare en 2026-10-20T12:50:24.000Z Novo's Obesity Drug Achieves 25% Weight Loss in Women in Late-Stage Trial Clinical Trials, Retatrutide https://retacompare.com/news/exploring-adult-weight-loss-drugs-for-pediatric-obesity-treatment 2026-10-20T11:31:06.951Z RetatrutideCompare en 2026-10-20T11:31:06.951Z Exploring Adult Weight-Loss Drugs for Pediatric Obesity Treatment Weight Loss, Retatrutide https://retacompare.com/news/comparing-oral-and-injectable-incretin-based-anti-obesity-therapies 2026-10-20T00:00:00.000Z RetatrutideCompare en 2026-10-20T00:00:00.000Z Comparing Oral and Injectable Incretin-Based Anti-Obesity Therapies Clinical Trials, Retatrutide https://retacompare.com/news/tirzepatide-shows-promise-for-obstructive-sleep-apnea-and-cardiometabolic-health 2026-10-20T00:00:00.000Z RetatrutideCompare en 2026-10-20T00:00:00.000Z Tirzepatide Shows Promise for Obstructive Sleep Apnea and Cardiometabolic Health Clinical Trials, Retatrutide https://retacompare.com/news/exploring-dose-response-in-incretin-and-multi-agonist-obesity-treatments 2026-10-20T00:00:00.000Z RetatrutideCompare en 2026-10-20T00:00:00.000Z Exploring Dose-Response in Incretin and Multi-Agonist Obesity Treatments Clinical Trials, Retatrutide